Groupe la Francaise Sells 10,282 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Groupe la Francaise reduced its Thermo Fisher Scientific stake by 9.1% in the second quarter, selling 10,282 shares and retaining 103,203 shares valued at approximately $51.5 million. Institutional investors own 89.23% of the company.
• Thermo Fisher reported strong quarterly results, with earnings of $6.03 per share and revenue of $11.99 billion, exceeding analyst expectations and representing 10.5% year-over-year revenue growth.
• The stock opened at $612.75, while analysts maintain a “Moderate Buy” consensus with an average price target of $619.41. The company also declared a quarterly dividend of $0.47 per share, yielding about 0.3%.

Groupe la Francaise lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,203 shares of the medical research company's stock after selling 10,282 shares during the period. Groupe la Francaise's holdings in Thermo Fisher Scientific were worth $51,513,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. Kilter Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $25,000. Legacy Wealth Managment LLC ID raised its holdings in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Finally, Birchwood Financial Partners Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company's stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.2%

Shares of NYSE TMO opened at $612.75 on Monday. The stock has a market capitalization of $226.56 billion, a P/E ratio of 32.96, a PEG ratio of 2.57 and a beta of 0.85. The stock's fifty day moving average is $570.91 and its 200 day moving average is $515.17. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 28th. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price on the stock. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Finally, Barclays upped their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.